摘要
目的: 研究特布他林联合糖皮质激素与谷胱甘肽治疗慢阻肺急性加重期(AECOPD)的疗效及对患者炎症因子水平的影响。 方法: 将医院2017.12~2018.12间收治的150例AECOPD患者纳为研究对象,根据患者临床用药方案,将其分为A组(特布他林,n=35)、B组(特布他林+糖皮质激素,n=61)与C组(特布他林+糖皮质激素+谷胱甘肽,n=54),观察三组治疗效果。 结果: 三组治疗有效率差异显著(P<0.05),其中C组治疗有效率最高,其次为B组,A组治疗有效率最低;经治疗后,咳嗽、咳痰及气促积分在A、B、C三组中呈依次下降趋势,组间差异显著(P<0.05);经治疗后,用力肺活量(FVC)、1s用力呼气容积(FEV1)及FEV1/FVC水平在A组、B组、C组三组中均呈依次上升趋势,且组间差异显著(P<0.05);经治疗后,血清C反应蛋白(CRP)及肿瘤坏死因子-α(TNF-α)水平在A、B、C三组中呈依次下降趋势,组间差异显著(P<0.05);三组药物不良反应无显著性差异(P>0.05)。 结论: 特布他林联合糖皮质激素与谷胱甘肽能有效改善AECOPD患者肺功能、缓解患者临床症状并降低机体炎症因子含量,提高治疗有效率,且药物不良反应小。
Objective: To study the efficacy of terbutaline combined with glucocorticoid and glutathione in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and its effects on inflammatory factors. Methods: 150 patients with AECOPD admitted to the hospital from December 2017 to December 2018 were included in the study. According to the clinical drug regimens, they were divided into group A (tebutaline, n=35) and group B (tebutaline +glucocorticoid, n=61) and group C (tebutaline + glucocorticoid + glutathione, n=54). The treatment effects were observed in the three groups. Results: There was a significant difference in the effective rate of treatment among the three groups (P<0.05), and the effective rate of treatment was the highest in group C, followed by group B, the lowest in group A. After treatment, the scores of cough, expectoration and shortness of breath in groups A, B and C showed downward trends in turn (P<0.05). After treatment, the levels of forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and FEV1/FVC showed upward trend in turn in group A, group B and group C (P<0.05). After treatment, the levels of serum C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) showed downward trends in groups A, B and C (P<0.05). There were no significant differences in the adverse drug reactions among the three groups (P>0.05). Conclusion: Terbutaline combined with glucocorticoid and glutathione can effectively improve lung function, relieve clinical symptoms, reduce the body inflammatory factors, and improve effective rate of treatment in patients with AECOPD, and it has few adverse drug reactions.
作者
刘晓冬
胡克
LIU Xiaodong;HU Ke(People's Hospital of Wuhan University,Hubei Wuhan 430060,China)
出处
《河北医学》
CAS
2020年第1期71-75,共5页
Hebei Medicine
基金
湖北省卫生厅科研项目,(编号:14071054)
关键词
特布他林
糖皮质激素
谷胱甘肽
慢阻肺急性加重期
Terbutaline
Glucocorticoid
Glutathione
Acute exacerbation of chronic obstructive pulmonary disease
